

This article was downloaded by:

On: 22 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713454007>

### A novel macrocyclic spermine alkaloid from *Incarvillea sinensis*

Y. -M. Chi<sup>a</sup>; M. Nakamura<sup>a</sup>; X. -Y. Zhao<sup>a</sup>; T. Yoshizawa<sup>a</sup>; W. -M. Yan<sup>b</sup>; F. Hashimoto<sup>c</sup>; Y. -C. Chi<sup>c</sup>; J. Kinjo<sup>d</sup>; T. Nohara<sup>d</sup>

<sup>a</sup> Seiwa Pharmaceutical. Ltd, Ibaraki, Japan <sup>b</sup> Beijing University of Traditional Chinese Medicine and Pharmacy, Beijing, China <sup>c</sup> Faculty of Agriculture, Kagoshima University, Kagoshima, Japan <sup>d</sup> Faculty of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan

**To cite this Article** Chi, Y. -M. , Nakamura, M. , Zhao, X. -Y. , Yoshizawa, T. , Yan, W. -M. , Hashimoto, F. , Chi, Y. -C. , Kinjo, J. and Nohara, T.(2007) 'A novel macrocyclic spermine alkaloid from *Incarvillea sinensis*', Journal of Asian Natural Products Research, 9: 2, 115 – 118

**To link to this Article: DOI:** 10.1080/10286020500289212

**URL:** <http://dx.doi.org/10.1080/10286020500289212>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## A novel macrocyclic spermine alkaloid from *Incarvillea sinensis*

Y.-M. CHI†, M. NAKAMURA†, X.-Y. ZHAO†, T. YOSHIZAWA†, W.-M. YAN‡, F. HASHIMOTO§, Y.-C. CHI§, J. KINJO|| and T. NOHARA||

†Seiwa Pharmaceutical. Ltd, Ibaraki 319-1535, Japan

‡Beijing University of Traditional Chinese Medicine and Pharmacy, Beijing 100029, China

§Faculty of Agriculture, Kagoshima University, Kagoshima 890-0065, Japan

||Faculty of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan

(Received 14 April 2005; revised 8 July 2005; in final form 14 July 2005)

A novel macrocyclic spermine alkaloid incasine C' (1), along with a known compound incasine C (2), were isolated from the whole plants of *Incarvillea sinensis*, and their structures were elucidated on the basis of chemical and spectroscopic evidence.

**Keywords:** *Incarvillea sinensis*; Bignoniaceae; Spermine alkaloid; Incasine C'

### 1. Introduction

The whole plants of *Incarvillea sinensis* Lam. (Bignoniaceae) have been used to treat rheumatism and to relieve pain as a traditional Chinese crude drug designated as 'Tougucao'. In studies on its pharmacological active substances, five novel macrocyclic spermine alkaloids [1] and 12 novel monoterpene alkaloids [2–8] have been isolated and characterised. One of the monoterpene alkaloids, incarvillateine, was found to show more potent anti-nociceptive activity than morphine in the formalin test, and the mechanism of anti-nociception was regarded to be different from that of morphine [9]. In this paper, we describe the isolation and structural elucidation of a novel macrocyclic spermine alkaloid, incasine C' (1).

### 2. Results and discussion

The whole plants of *I. sinensis* were extracted with EtOH, and the extract was subsequently treated with weak acid and alkali, followed by Al<sub>2</sub>O<sub>3</sub> and silica gel column chromatographies

\*Corresponding author. Email: chi-59@unimatec.co.jp

and preparative HPLC separation to yield a novel compound incasine C' (1), together with a known compound incasine C (2).

Compound 1 was obtained as an off-white amorphous powder. Its molecular formula  $C_{29}H_{38}N_4O_2$  was provided by HREI-MS (at  $m/z$  474.2987  $[M]^+$ ). The  $^1H$  NMR and  $^{13}C$  NMR spectra of 1 were quite similar to those of compound 2 except for the signals at  $\delta$  6.80, 6.81 (each 0.5H, d,  $J = 15.4$  Hz) and 7.71, 7.73 (each 0.5H, d,  $J = 15.4$  Hz) in the  $^1H$  NMR spectrum, and at  $\delta$  142.0, 142.2 (d) and 117.1, 117.3 (d) in the  $^{13}C$  NMR spectrum [1]. It was noted that a complexity, mostly with doublet signals for each carbon assignment in the  $^{13}C$  NMR spectrum was due to the presence of *E*- and *Z*-isomers of the amide groups [10]. Its EI-MS exhibited the same molecular ion peak at  $m/z$  474 and MS fragmentation as compound 2. A peak at  $m/z$  139 was recognised as a characteristic fragment ion which was due to the initial cleavage of an unstable bond between C-8 and N-9, followed by a process of splitting bond and of hydrogen transfer between N-1 and C-17, suggesting a methylene group was attached to N-9 and N-13 on a 17-membered lactam ring [11]. In the  $^1H$  NMR spectrum, signals at  $\delta$  6.80, 6.81 (each 0.5H, d,  $J = 15.4$  Hz) and 7.71, 7.73 (each 0.5H, d,  $J = 15.4$  Hz) were assigned as a pair of olefinic protons, suggesting the presence of an amidically bounded *trans*-cinnamoyl residue. In addition, catalytic hydrogenation of compounds 1 and 2 with 10% Pd/C under  $H_2$  yielded one and the same saturated product 3. Thus, the structure of 1 was established as described in figure 1.

In order to confirm the absolute configuration involving a chirality at C-8 position, the CD spectrum of its saturated product 3 was compared with those of (*R*)-(+)- and (*S*)-(–)- $\alpha$ -phenylethylamines [12,13]. The CD spectrum of 3 was shown to be quite similar to that of (*R*)-(+)- $\alpha$ -phenylethylamine, thus the absolute configuration was determined to be *R*.

### 3. Experimental

#### 3.1 General experimental procedures

$^1H$  NMR and  $^{13}C$  NMR spectra were obtained with a JEOL  $\alpha$ -500 spectrometer, and chemical shifts were given on a  $\delta$  (ppm) scale with tetramethylsilane as an internal standard. EI-MS were recorded on a JEOL DX-303 HF spectrometer. CD spectra were measured on a JASCO J-720 spectrometer. TLC: pre-coated Kieselgel 60 F<sub>254</sub> plate (0.2 mm, Merck), detection by spraying Dragendorff and 10% aq.  $H_2SO_4$ . CC: Kieselgel 60 (70–230 and 230–400 mesh, Merck), Aluminium oxide 90 aktiv (70–230 mesh, Merck). Preparative HPLC




Figure 1. Structures of compounds 1–3.

separation was performed on a Hewlett–Packard (HP) Agilent 1100 series HPLC system (Agilent, Yokogawa Analytical Systems, Tokyo, Japan), with a diode array detector operating at 253 nm. The column used in this study was Hydrosphere C18 (5  $\mu\text{m}$ , 250  $\times$  20 mm i.d., YMC Co. Ltd., Japan).

### 3.2 Plant material

The dried whole plants of *I. sinensis* were collected in Qingdao of Shandong province, China in August 1999, and identified by the fifth author. A voucher specimen was deposited at the Herbarium of Beijing University of Traditional Chinese Medicine and Pharmacy.

### 3.3 Extraction and isolation

The whole plants (2.0 kg) were extracted twice with 95% EtOH for 2 h and the combined extracts were concentrated to a syrup at 60°C. The residue was then dissolved in 1% HCl and filtered. The filtrate was adjusted to pH 10–11 by adding  $\text{NH}_4\text{OH}$ , and the alkaloid was extracted with  $\text{CHCl}_3$ . After removal of the solvent *in vacuo* to dryness to give a residue (8.6 g), which was repeatedly subjected to  $\text{Al}_2\text{O}_3$  column chromatography with  $\text{CHCl}_3$ – $\text{MeOH}/\text{H}_2\text{O}$  (10:1:0  $\rightarrow$  6:4:1) as eluant and silica gel column chromatography with cyclohexane/EtOH/Et<sub>2</sub>NH (40:1:1  $\rightarrow$  5:1:1). The fractions were combined on the basis of their behaviour on TLC. A fraction seemed to be a pure substance according to its TLC behaviour; however, the multiplicity of <sup>1</sup>H NMR and <sup>13</sup>C NMR spectral data, and HPLC behaviour, showed it to be a mixture of *cis* and *trans* isomers. Further separation was performed by reverse-phase HPLC elution with  $\text{CH}_3\text{CN}/40 \text{ mM } \text{KH}_2\text{PO}_4$  (23:77) to give compounds 1 (13 mg) and 2 (18 mg).

**3.3.1 Incasine C' (1).** An off-white amorphous powder,  $[\alpha]_D^{24} + 6.4$  ( $\text{CHCl}_3$ , *c* 0.08). <sup>1</sup>H NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$ : 1.26–1.87 (8H, m, H-3, 11, 15, 16), 2.30–3.78 (16H, m, H-2, 4, 7, 10, 12, 14, 17, 18), 3.98 (1H, m, H-8), 6.80, 6.81 (each 0.5H, d, *J* = 15.4 Hz, H-7'), 7.71, 7.73 (each 0.5H, d, *J* = 15.4 Hz, H-8'), 7.09, 7.29–7.42, 7.52 (10H, m, H-2', 3', 4', 5', 6', 2'', 3'', 4'', 5'', 6''). <sup>13</sup>C NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$ : 21.2, 21.3, 25.3, 25.6, 26.7, 26.9, 29.6, 29.7 (C-3, 11, 15, 16), 35.8, 36.4, 43.8, 44.1, 45.8, 47.2, 47.6, 50.8, 53.4, 53.7 (C-2, 4, 7, 10, 12, 14, 17, 18), 64.0 (C-8), 117.1, 117.3 (C-8'), 127.6, 127.7, 127.8, 127.9, 128.1, 128.3, 128.4, 128.6, 128.7, 129.3, 129.4 (C-2', 3', 4', 5', 6', 2'', 3'', 4'', 5'', 6''), 135.1, 135.2 (C-1'), 142.0, 142.2 (C-7'), 142.5, 142.6 (C-1''), 165.6, 165.7 (C-9'), 171.7, 171.8 (C-6). EI-MS (*m/z*): 474 ( $[\text{M}]^+$ , 21), 473 (28), 314 (35), 196 (17), 194 (18), 180 (22), 178 (15), 139 (17), 138 (18), 131 (23), 111 (31), 107 (27), 95 (24), 83 (35), 71 (39), 70 (36), 43 (100). HREI-MS (*m/z*): 474.2987 (calcd for  $\text{C}_{29}\text{H}_{38}\text{N}_4\text{O}_2$ , 474.2997).

**3.3.2 7',8'-dihydroincasine C (3).** A white powder,  $[\alpha]_D^{25} + 8.6$  ( $\text{CHCl}_3$ , *c* 0.62). EI-MS (*m/z*): 476 ( $[\text{M}]^+$ , 90), 475 (100), 421 (19), 131 (18), 125 (12), 111 (13), 105 (28), 98 (17), 91 (38), 84 (28), 70 (12). <sup>1</sup>H NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$ : 1.47–1.83 (8H, m, H-3, 11, 15, 16), 2.37–3.90 (20H, m, H-2, 4, 7, 10, 12, 14, 17, 18, 7', 8'), 3.98 (1H, m, H-8), 7.08, 7.20, 7.26–7.35 (10H, m, H-2', 3', 4', 5', 6', 2'', 3'', 4'', 5'', 6''). CD (MeOH, *c* = 6.7 mg/2 ml, 220–300

nm):  $[\theta]_{249} 0$ ,  $[\theta]_{250} - 1010$  (peak),  $[\theta]_{252} + 270$  (trough),  $[\theta]_{254} - 1562$  (peak),  $[\theta]_{256} - 511$  (trough),  $[\theta]_{260} - 2267$  (peak),  $[\theta]_{264} - 851$  (trough),  $[\theta]_{266} - 2261$  (peak),  $[\theta]_{273} 0$ .

## References

- [1] Y.M. Chi, F. Hashimoto, W.M. Yan, T. Nohara. *Tetrahedron Lett.*, **38**, 2713 (1997).
- [2] Y.M. Chi, W.M. Yan, J.S. Li. *Phytochemistry*, **29**, 2376 (1990).
- [3] Y.M. Chi, W.M. Yan, D.C. Chen, H. Noguchi, Y. Iitaka, U. Sankawa. *Phytochemistry*, **31**, 2930 (1992).
- [4] Y.M. Chi, F. Hashimoto, W.M. Yan, T. Nohara. *Phytochemistry*, **39**, 1485 (1995).
- [5] Y.M. Chi, F. Hashimoto, W.M. Yan, T. Nohara. *Phytochemistry*, **40**, 353 (1995).
- [6] Y.M. Chi, F. Hashimoto, W.M. Yan, T. Nohara, M. Yamashita, N. Marubayashi. *Chem. Pharm. Bull.*, **45**, 495 (1997).
- [7] Y.M. Chi, F. Hashimoto, W.M. Yan, T. Nohara. *Phytochemistry*, **46**, 763 (1997).
- [8] M. Nakamura, Y.M. Chi, J. Kinjo, W.M. Yan, T. Nohara. *Phytochemistry*, **51**, 595 (1999).
- [9] M. Nakamura, Y.M. Chi, W.M. Yan, Y. Nagasugi, T. Yoshizawa, N. Irino, F. Hashimoto, J. Kinjo, T. Nohara, S. Sakurada. *J. Nat. Prod.*, **62**, 1293 (1999).
- [10] Z. Kobicova, F. Turecek, P. Ninova, J. Trojanek, K. Blaha. *Tetrahedron Lett.*, **24**, 4381 (1983).
- [11] K. Drandarov. *Tetrahedron Lett.*, **36**, 617 (1995).
- [12] H.E. Smith, M.E. Warren, L.I. Katzin. *Tetrahedron*, **24**, 1327 (1968).
- [13] K. Seifert, S. Johne, M. Hesse. *Helv. Chim. Acta*, **65**, 2540 (1982).